Abiraterone Therapy Duration and Management in Metastatic Castration‑Resistant Prostate Cancer

1. Treatment Continuation Recommendations

The NCCN recommends that abiraterone be continued indefinitely until clinical progression or intolerable toxicity, with no provision for elective discontinuation after a fixed time period. 1
Discontinuing effective abiraterone in patients who remain progression‑free after 4–5 years is not advised, because all pivotal trials kept therapy ongoing until progression, unacceptable toxicity, or death. 2

In the COU‑AA‑301 trial, the median treatment duration was 8 months, reflecting disease progression rather than planned drug cessation. 3
In the COU‑AA‑302 trial, patients were followed for a median of 49.2 months, and those without progression remained on abiraterone throughout this period. 3

Monthly monitoring of liver function tests, serum potassium, phosphate, and blood pressure is mandated for the entire treatment course. (NCCN guideline) 3
Ongoing surveillance for cardiovascular symptoms is recommended, especially in individuals with pre‑existing cardiac disease. (NCCN) 3

A low‑dose regimen (250 mg daily) taken with a low‑fat breakfast has demonstrated non‑inferiority to the standard dose in a phase II trial, offering a cost‑effective option without compromising efficacy. (NCCN) 5
The fine‑particle formulation (500 mg daily with methylprednisolone 4 mg twice daily) is bio‑equivalent to the standard formulation and can be used to improve tolerability. (NCCN) 3
For patients experiencing mineralocorticoid‑related side effects, switching from prednisone to dexamethasone 1 mg daily is advised, typically in the context of disease progression. (NCCN) 8

Radiologic imaging (CT and bone scan) and PSA testing should be performed every 3–4 months to identify progression early. (NCCN) 1
Therapy should continue through PSA or bone‑scan flare until confirmed clinical or radiographic progression, avoiding premature discontinuation based solely on biochemical changes. (NCCN) 1